PMID- 16791271
OWN - NLM
STAT- MEDLINE
DCOM- 20060816
LR  - 20130304
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 20
IP  - 8
DP  - 2006 Aug
TI  - Therapeutic use of granulocyte-colony stimulating factor could conceal residual 
      malignant cells in patients with AML1/ETO+ acute myelogenous leukemia.
PG  - 1408-13
AB  - We have experienced a number of cases of AML1/ETO+ acute myelogenous leukemia 
      that showed remission based on bone marrow (BM) morphological criteria, but that 
      revealed clonal abnormalities in most cells by fluorescence in situ hybridization 
      (FISH). Interestingly, most of these cases had AML with AML1/ETO rearrangement. 
      The malignant cells were differentiated and considered mature cells after 
      granulocyte-colony stimulating factor (G-CSF) treatment. To clarify the possible 
      mechanisms underlying this phenomenon, we investigated the expression levels of 
      G-CSFR in AML cells with AML1/ETO rearrangement by flow cytometry and real-time 
      polymerase chain reaction (PCR). The number of AML1/ETO+ cells expressing G-CSFR 
      at baseline was significantly higher than that of AML1/ETO- AML cells (2673 vs 
      522). In addition, the G-CSFR gene was more highly expressed in AML1/ETO+ cells 
      than in AML1/ETO- cells by real-time PCR. This study reveals that cases showing 
      remission after treatment with G-CSF mostly had leukemia with AML1/ETO 
      rearrangement. This finding might be explained by the higher expression of G-CSF 
      receptor in AML1/ETO+ cells than in AML1/ETO- cells. We recommend that remission 
      should be confirmed by FISH, because malignant clones can be differentiated and 
      masked in morphological examination or chromosome test, especially for AML with 
      AML1/ETO rearrangement.
FAU - Moon, H W
AU  - Moon HW
AD  - Department of Laboratory Medicine, Ewha Womens University College of Medicine, 
      Seoul, Korea.
FAU - Shin, S
AU  - Shin S
FAU - Kim, H Y
AU  - Kim HY
FAU - Kim, Y R
AU  - Kim YR
FAU - Cho, H I
AU  - Cho HI
FAU - Yoon, S S
AU  - Yoon SS
FAU - Park, S
AU  - Park S
FAU - Kim, B K
AU  - Kim BK
FAU - Chun, H
AU  - Chun H
FAU - Kim, H C
AU  - Kim HC
FAU - Park, C J
AU  - Park CJ
FAU - Min, Y H
AU  - Min YH
FAU - Lee, D S
AU  - Lee DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060622
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Core Binding Factor Alpha 2 Subunit)
RN  - 0 (RUNX1 protein, human)
RN  - 0 (Receptors, Granulocyte Colony-Stimulating Factor)
RN  - 143011-72-7 (Granulocyte Colony-Stimulating Factor)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Child
MH  - Core Binding Factor Alpha 2 Subunit/*genetics
MH  - Female
MH  - Flow Cytometry
MH  - *Gene Rearrangement
MH  - Granulocyte Colony-Stimulating Factor/*therapeutic use
MH  - Humans
MH  - Leukemia, Myeloid, Acute/*drug therapy/*genetics
MH  - Male
MH  - Middle Aged
MH  - Neoplasm, Residual
MH  - Polymerase Chain Reaction
MH  - Receptors, Granulocyte Colony-Stimulating Factor/analysis/genetics
EDAT- 2006/06/23 09:00
MHDA- 2006/08/17 09:00
CRDT- 2006/06/23 09:00
PHST- 2006/06/23 09:00 [pubmed]
PHST- 2006/08/17 09:00 [medline]
PHST- 2006/06/23 09:00 [entrez]
AID - 2404286 [pii]
AID - 10.1038/sj.leu.2404286 [doi]
PST - ppublish
SO  - Leukemia. 2006 Aug;20(8):1408-13. doi: 10.1038/sj.leu.2404286. Epub 2006 Jun 22.